^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lunsumio (mosunetuzumab-axgb)

    i
    Other names: RG7828, BTCT4465A, RG 7828, BTCT 4465A, RO7030816, CD20-TBD, BTCT-4465A, RG-7828, RO 7030816, RO-7030816
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    22h
    CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 positive
    |
    zeprumetostat (SHR-2554) • Lunsumio (mosunetuzumab-axgb)
    7d
    BO43243: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=137, Recruiting, Hoffmann-La Roche | Trial completion date: Feb 2030 --> Feb 2032 | Trial primary completion date: May 2028 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
    7d
    MorningSun: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (clinicaltrials.gov)
    P2, N=320, Active, not recruiting, Genentech, Inc. | Trial completion date: Jul 2028 --> Jul 2027 | Trial primary completion date: Jul 2028 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
    9d
    Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=15 --> 9
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Lunsumio (mosunetuzumab-axgb)
    14d
    Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico. (PubMed, Antibodies (Basel))
    The effectiveness of this drug is confirmed in our center.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Lunsumio (mosunetuzumab-axgb)
    15d
    UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov)
    P2, N=23, Recruiting, Abramson Cancer Center at Penn Medicine | N=42 --> 23
    Enrollment change
    |
    Gazyva (obinutuzumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    17d
    Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review. (PubMed, J Clin Exp Hematop)
    A 74-year-old woman with a history of FL, initially treated with R-CHOP and later with rituximab monotherapy, presented with progressive dyspnea and was found to have bilateral pleural effusion. This case suggests that mosunetuzumab may exert rapid antitumor activity in both systemic disease and malignant effusions, possibly through distribution into pleural fluid and subsequent T-cell-mediated cytotoxicity. Further studies are warranted to clarify the role of bispecific antibodies in malignant effusions associated with lymphoma.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Lunsumio (mosunetuzumab-axgb)
    21d
    SOLUNA: A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis (clinicaltrials.gov)
    P2, N=30, Recruiting, Hoffmann-La Roche
    New P2 trial
    |
    Lunsumio (mosunetuzumab-axgb)
    1m
    Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)
    1m
    Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • CD4 (CD4 Molecule)
    |
    TP53 mutation
    |
    clonoSEQ®
    |
    Lunsumio (mosunetuzumab-axgb)
    1m
    CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    CD20 positive
    |
    zeprumetostat (SHR-2554) • Lunsumio (mosunetuzumab-axgb)
    1m
    CaDAnCe-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=80, Recruiting, BeOne Medicines
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)